( NASDAQ-SMALL:XTLB, TelAviv:XTLB )

News from XTL Biopharmaceuticals Ltd A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

27 Apr, 2017, 09:50 ET XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of Directors

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing...


05 Apr, 2017, 09:10 ET XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögren’s Syndrome

- Additional data shows a statistically significant effect in the gene expression of two additional genes that have a role in...


30 Mar, 2017, 08:55 ET XTL Biopharmaceuticals Reports 2016 Financial Results & Provides Clinical and Operational Update

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing...


22 Mar, 2017, 09:22 ET XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement From Existing Investors

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE:XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing...


07 Mar, 2017, 12:40 ET XTL Biopharmaceuticals Announces $2.8 Million Private Placement From Existing Investors

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE:XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing...


01 Mar, 2017, 08:30 ET XTL Biopharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing...


17 Feb, 2017, 08:00 ET XTL Biopharmaceuticals Announces $2.5 Million Registered Direct Offering

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE:XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing...


13 Feb, 2017, 09:08 ET XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome

- Dr. Robert I. Fox and Professor Simon Bowman are world-renowned rheumatologists and experts in Sjogren's syndrome - XTL...


25 Jan, 2017, 08:30 ET XTL Biopharmaceuticals Announces Ratio Change of its Depositary Receipt Program

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing...


05 Jan, 2017, 08:30 ET XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjögren's Syndrome

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing...


19 Dec, 2016, 08:00 ET XTL Biopharmaceuticals to Present at Biotech Showcase

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


06 Dec, 2016, 08:30 ET XTL Biopharmaceuticals Reports Third Quarter 2016 Financial Results & Provides Clinical and Operational Update

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


09 Nov, 2016, 13:25 ET XTL Biopharmaceuticals Receives NASDAQ Notification Regarding Minimum Bid Requirements

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


27 Sep, 2016, 08:30 ET XTL Biopharmaceuticals Reports Second Quarter 2016 Financial Results & Provides Clinical and Operational Update

 XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its...


07 Sep, 2016, 08:32 ET XTL Biopharmaceuticals Announces the European Patent Office has Issued a Patent for its Lupus Drug hCDR1

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


06 Sep, 2016, 08:00 ET XTL Biopharmaceuticals to Present at Rodman & Renshaw Conference on September 12, 2016

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


11 Aug, 2016, 09:00 ET XTL Biopharmaceuticals Announces New Patent Filing in U.S. for Lupus Drug hCDR1

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


01 Jun, 2016, 08:30 ET XTL Biopharmaceuticals Reports First Quarter 2016 Financial Results & Provides Clinical and Operational Update

 XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing...


21 Mar, 2016, 08:30 ET XTL Biopharmaceuticals Completes Phase 2 Trial Design for Lead Compound hCDR1 in the Treatment of Lupus

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


09 Mar, 2016, 08:29 ET Lupus Thought Leader Daphna Paran, MD, Named Medical Director of XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


22 Feb, 2016, 09:02 ET XTL Biopharmaceuticals Receives European Medicines Agency's SME Status

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


10 Feb, 2016, 08:30 ET XTL Biopharmaceuticals' Lupus Drug hCDR1 Granted Patent for Pharmaceutical Composition & Manufacturing Processes

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


27 Jan, 2016, 08:30 ET XTL Biopharmaceuticals Joins Corporate Advisory Council of the Lupus Foundation of America

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


25 Jan, 2016, 08:30 ET XTL Biopharmaceuticals Announces Encouraging Feedback from U.S. FDA on its Upcoming IND Filing for Lupus Drug hCDR1

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


13 Jan, 2016, 08:30 ET XTL Biopharmaceuticals Advances Formulation of its hCDR1 Drug for Clinical Trials in the Treatment of Lupus Through use of Cydex Pharmaceuticals' Captisol®

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...